Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name MYD88 L265P
Gene Variant Detail

MYD88 L265P (gain of function)

Relevant Treatment Approaches Bazlitoran Ibrutinib

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
MYD88 L265P diffuse large B-cell lymphoma not applicable N/A Clinical Study Prognostic In multiple clinical studies, MYD88 L265P was associated with a worse overall survival in patients with diffuse large B-cell lymphoma when compared to MYD88 wild-type (PMID: 24903481, PMID: 25055137, PMID: 26792260). 26792260 24903481 25055137
MYD88 L265P B-cell lymphoma sensitive Bazlitoran Bazlitoran Preclinical - Cell line xenograft Actionable In a preclinical study, treatment with IMO-8400 resulted in decreased survival of B-cell lymphoma cell lines harboring MYD88 L265P in culture, and decreased tumor growth in a MYD88 L265P-positive B-cell lymphoma cell line xenograft models (Cancer Res October 1, 2014 74:2570). detail...
MYD88 L265P central nervous system lymphoma sensitive Ibrutinib Ibrutinib Phase I Actionable In a Phase I trial, two patients with primary central nervous system lymphoma each harboring MYD88 L265P demonstrated a complete response when treated with Imbruvica (ibrutinib) (PMID: 28619981). 28619981
MYD88 L265P diffuse large B-cell lymphoma resistant Ibrutinib Ibrutinib Phase II Actionable In a Phase II trial, all of diffuse large B-cell lymphoma patients harboring MYD88 L265P (n=4) did not respond to Imbruvica (ibrutinib) treatment (Blood 2012, 120 (21): 686). detail...
MYD88 L265P non-Hodgkin lymphoma no benefit Ibrutinib Ibrutinib Preclinical - Pdx Actionable In a preclinical study, a non-Hodgkin lymphoma (NHL) patient derived xenograft (PDX) model harboring both CD79B Y197N and MYD88 L265P demonstrated sensitivity to Ibruvica (ibrutinib) while an NHL patient derived xenograft (PDX) model harboring only MYD88 L265P did not respond to Ibruvica (ibrutinib) (ASH 57th Annual Meeting, 2015, abstract #2759). detail...
MYD88 L265P diffuse large B-cell lymphoma sensitive Vorinostat Preclinical - Cell culture Actionable In a preclinical study, a diffuse large B-cell lymphoma cell line harboring MYD88 L256P demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased apoptosis (PMID: 27733371). 27733371
MYD88 L265P Waldenstroem's macroglobulinemia not applicable N/A Guideline Diagnostic MYD88 L265P is diagnostic and aids distinguishing Waldenstrom macroglobulinemia from IgM-secreting B-cell lymphomas and IgM plasma cell myeloma (NCCN.org). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02252146 Phase Ib/II Bazlitoran Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88L265P Mutation Completed
NCT04274738 Phase I Ibrutinib + X4P-001 A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 Recruiting